Lymphangioleiomyomatosis Clinical Trials

9 recruiting

Lymphangioleiomyomatosis Trials at a Glance

10 actively recruiting trials for lymphangioleiomyomatosis are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 1 with 2 trials, with the heaviest enrollment activity in Cincinnati, Bethesda, and Cleveland. Lead sponsors running lymphangioleiomyomatosis studies include National Heart, Lung, and Blood Institute (NHLBI), Dr.Deborah Yates, and David M. Ritter.

Browse lymphangioleiomyomatosis trials by phase

Treatments under study

About Lymphangioleiomyomatosis Clinical Trials

Looking for clinical trials for Lymphangioleiomyomatosis? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Lymphangioleiomyomatosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Lymphangioleiomyomatosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 110 of 10 trials

Recruiting
Phase 1Phase 2

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

Lymphangioleiomyomatosis
National Heart, Lung, and Blood Institute (NHLBI)100 enrolled1 locationNCT01799538
Recruiting

Study of the Disease Process of Lymphangioleiomyomatosis

PneumothoraxLymphangioleiomyomatosisLung Disease+1 more
National Heart, Lung, and Blood Institute (NHLBI)2,000 enrolled1 locationNCT00001465
Recruiting

Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)

LymphangioleiomyomatosisTuberous Sclerosis Complex
David M. Ritter300 enrolled1 locationNCT06160310
Recruiting
Phase 1

Evaluating the Long-term Safety and Tolerability of Imatinib in Patients With Lymphangioleiomyomatosis (LAM)

LymphangioleiomyomatosisLymphangioleiomyomatosis (LAM)
Columbia University20 enrolled2 locationsNCT06889168
Recruiting

Role of Extracellular Vesicles as Biomarkers of Pulmonary Involvement in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex

Lymphangioleiomyomatosis (LAM)Extracellular Vesicles; Generation and Function
University of Milan80 enrolled1 locationNCT07304856
Recruiting

TSC Biosample Repository and Natural History Database

LymphangioleiomyomatosisTuberous Sclerosis
National Tuberous Sclerosis Association5,000 enrolled24 locationsNCT05676099
Recruiting

National Lymphangioleiomyomatosis Registry, France

Lymphangioleiomyomatosis
Vincent COTTIN200 enrolled1 locationNCT01484236
Recruiting

Safety and Durability of Sirolimus for Treatment of LAM

Lymphangioleiomyomatosis
University of Cincinnati600 enrolled20 locationsNCT02432560
Recruiting

The Genotype and Phenotype of Lymphangioleiomyomatosis

Sporadic LymphangioleiomyomatosisTSC-associated Lymphangioleiomyomatosis
National Taiwan University Hospital100 enrolled1 locationNCT06405997
Recruiting
Phase 2

Doxycycline in Lymphanioleiomyomatosis (LAM): a randomised double blind placebo controlled crossover trial

Lymphangioleiomyomatosis
Dr.Deborah Yates30 enrolled1 locationACTRN12608000325303